Inflammatory bowel disease (IBD) refers a group of chronic inflammatory disease affecting the intestines; namely, ulcerative colitis (UC) and Crohn’s disease (CD). IBD affects between 2.4 and 3.1 million adults in the United States, conferring substantial disease burden. Despite therapeutic …
The role of precision medicine in the treatment of IBD has been increasingly recognized as essential for improving patient outcomes. Precision medicine aims to tailor therapeutic approaches based on individual patient characteristics, including genetic, molecular, and environmental factors. This personalized …
Short bowel syndrome (SBS), a rare malabsorption disorder most often caused by surgical resection, can be challenging to manage. The use of parenteral nutrition (PN) and emerging therapies promoting enteral autonomy have offered hope, however, complications of SBS and its …
Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …
To improve the quality of care for patients with Alzheimer’s disease (AD), health care professionals (HCPs) are positioned to assess brain health and provide the crucial early diagnosis, especially in diverse, underserved patient populations. HCPs must implement emerging care strategies, …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of the latest clinical trial data and its translation to real-world …
It is critically important that health care professionals screen for and diagnose Alzheimer’s disease (AD) in its early stages when symptoms are subtle and resemble normal aging, as brain changes may start years before symptoms manifest and the underlying pathology …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …